Gland Pharma Q2FY27 Financial and Operational Performance Summary
Gland Pharma Ltd · Investor Presentation · 06 Nov 2026, 10:32 pm
Gland Pharma Q2FY27 Financial and Operational Performance Summary Gland Pharma reported Q2FY27 consolidated revenue of ₹18,336 Mn, up 23% YoY, driven by 42% YoY growth in the US market (64% revenue share) and 30% YoY growth in Europe. EBITDA surged 53% YoY to ₹4,804 Mn with margins expanding 500 bps to 26%, while PAT rose 58% YoY to ₹2,908 Mn. The company launched 4 molecules in the US, filed 11 ANDAs, and received 10 approvals. Cash and bank balances stood at ₹34,412 Mn with net cash of ₹32,216 Mn.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Unaudited Financial Results for the Quarter and half year ended September 30, 2026 · 06 Nov 2026
